AbbVie Inc. (NYSE:ABBV) Shares Bought by Sigma Planning Corp


Share on StockTwits

Sigma Planning Corp boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 121,470 shares of the company’s stock after acquiring an additional 3,554 shares during the period. Sigma Planning Corp’s holdings in AbbVie were worth $13,016,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ABBV. James Investment Research Inc. purchased a new stake in AbbVie in the third quarter valued at approximately $32,000. Pinnacle Associates Ltd. raised its holdings in shares of AbbVie by 3.4% during the third quarter. Pinnacle Associates Ltd. now owns 47,604 shares of the company’s stock worth $4,170,000 after purchasing an additional 1,551 shares during the period. Tradewinds Capital Management LLC raised its holdings in shares of AbbVie by 18.6% during the third quarter. Tradewinds Capital Management LLC now owns 1,178 shares of the company’s stock worth $103,000 after purchasing an additional 185 shares during the period. Cypress Asset Management Inc. TX raised its holdings in shares of AbbVie by 2.4% during the third quarter. Cypress Asset Management Inc. TX now owns 14,653 shares of the company’s stock worth $1,283,000 after purchasing an additional 345 shares during the period. Finally, Landsberg Bennett & Dubbaneh LLC raised its holdings in shares of AbbVie by 2.7% during the third quarter. Landsberg Bennett & Dubbaneh LLC now owns 7,004 shares of the company’s stock worth $609,000 after purchasing an additional 182 shares during the period. 67.49% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently weighed in on ABBV. Royal Bank of Canada increased their price objective on shares of AbbVie from $129.00 to $135.00 and gave the stock an “outperform” rating in a report on Thursday, February 4th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $114.00 target price for the company in a research report on Tuesday, February 9th. BMO Capital Markets initiated coverage on shares of AbbVie in a research report on Wednesday, November 18th. They issued an “outperform” rating and a $123.00 target price for the company. Morgan Stanley decreased their target price on shares of AbbVie from $120.00 to $116.00 and set an “overweight” rating for the company in a research report on Thursday, January 28th. Finally, Mizuho increased their target price on shares of AbbVie from $117.00 to $126.00 and gave the company a “buy” rating in a research report on Thursday, February 4th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company. AbbVie has an average rating of “Buy” and an average price target of $114.39.

In other news, EVP Jeffrey Ryan Stewart sold 25,290 shares of the stock in a transaction on Tuesday, December 29th. The stock was sold at an average price of $105.00, for a total value of $2,655,450.00. Following the completion of the sale, the executive vice president now owns 76,259 shares in the company, valued at $8,007,195. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy J. Richmond sold 51,990 shares of the stock in a transaction on Friday, November 27th. The shares were sold at an average price of $105.00, for a total value of $5,458,950.00. Following the completion of the sale, the executive vice president now owns 51,990 shares of the company’s stock, valued at approximately $5,458,950. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Shares of NYSE:ABBV traded down $0.60 during trading hours on Tuesday, hitting $106.46. 214,713 shares of the company’s stock traded hands, compared to its average volume of 7,651,642. AbbVie Inc. has a 52 week low of $62.55 and a 52 week high of $113.41. The company has a debt-to-equity ratio of 5.38, a quick ratio of 0.81 and a current ratio of 0.95. The company’s fifty day simple moving average is $107.18 and its two-hundred day simple moving average is $97.93. The company has a market cap of $187.95 billion, a price-to-earnings ratio of 22.66, a price-to-earnings-growth ratio of 1.54 and a beta of 0.84.

AbbVie (NYSE:ABBV) last announced its earnings results on Tuesday, February 2nd. The company reported $2.92 EPS for the quarter, topping the consensus estimate of $2.85 by $0.07. AbbVie had a net margin of 18.16% and a return on equity of 439.24%. The company had revenue of $13.86 billion during the quarter, compared to analysts’ expectations of $13.70 billion. During the same period last year, the company posted $2.21 earnings per share. The business’s revenue for the quarter was up 59.2% on a year-over-year basis. On average, analysts anticipate that AbbVie Inc. will post 10.48 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 14th. Investors of record on Thursday, April 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 4.88%. The ex-dividend date of this dividend is Wednesday, April 14th. AbbVie’s dividend payout ratio is 58.17%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Further Reading: Backdoor Roth IRA Conversion and Strategy

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.